EP Patent

EP4617278A1 — Nucleotide analog, and composition and use thereof

Assigned to Shenzhen Targetrx Inc · Expires 2025-09-17 · 1y expired

What this patent protects

The present invention relates to a compound of formula (I) or a tautomer, a stereoisomer, a prodrug, a crystalline form, a pharmaceutically acceptable salt, a hydrate or a solvate thereof, a pharmaceutical composition thereof, and use of these substances in the treatment and/or p…

USPTO Abstract

The present invention relates to a compound of formula (I) or a tautomer, a stereoisomer, a prodrug, a crystalline form, a pharmaceutically acceptable salt, a hydrate or a solvate thereof, a pharmaceutical composition thereof, and use of these substances in the treatment and/or prevention of viral infections.

Drugs covered by this patent

Patent Metadata

Patent number
EP4617278A1
Jurisdiction
EP
Classification
Expires
2025-09-17
Drug substance claim
No
Drug product claim
No
Assignee
Shenzhen Targetrx Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.